Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: A decentralization pilot study

Madisa Mine, Keabetswe Bedi, Talkmore Maruta, Dignity Madziva, Modiri Tau, Tatenda Zana, Tendani Gaolathe, Sikhulile Moyo, Khumo Seipone, Ndwapi Ndwapi, Max Essex, Richard Marlink

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Roche COBAS Amplicor monitor version 1.5 assay is considered gold standard for viral load monitoring in Botswana. Due to its demand for elaborate infrastructure, viral load testing has been confined to the national HIV reference laboratories. Cavidi ExaVir Load version 2 assay was considered as a potential alternative to decentralize viral load testing to the rural/remote hospital laboratories and thus increase access to therapy. This study compared the performance of ExaVir Load v2 assay at a district hospital laboratory in Serowe and COBAS Amplicor monitor v1.5 assay at the Botswana Harvard HIV Reference Laboratory using quality assessment samples and plasma from HIV-positive individuals. ExaVir Load v2 and COBAS Amplicor monitor v1.5 assays had very good agreement; Kappa statistic 0.951. The COBAS Amplicor monitor v1.5 and ExaVir Load v2 assays detected HIV-1 RNA in 84 and 86 samples but did not detect HIV-1 RNA in 221 and 219 samples, respectively. The two assays detected HIV-1 RNA concordantly in 82 samples and were strongly correlated (r = 0.8554, P < 0.0001). ExaVir Load v2 assay provided a simple and reliable alternative viral load system that is adaptable to district hospital laboratories. The cost per test is less than RT-PCR. The ExaVir Load v2 systems have since been placed in four more district and primary hospital laboratories.

Original languageEnglish (US)
Pages (from-to)93-97
Number of pages5
JournalJournal of Virological Methods
Volume159
Issue number1
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Botswana
Hospital Laboratories
District Hospitals
RNA-Directed DNA Polymerase
Politics
Viral Load
HIV-1
HIV
RNA
Rural Hospitals
Costs and Cost Analysis
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Virology

Keywords

  • Cavidi ExaVir Load
  • HIV-1 RNA
  • HIV-1 RT
  • Resource limited
  • Roche COBAS Amplicor
  • Viral load

Cite this

Mine, Madisa ; Bedi, Keabetswe ; Maruta, Talkmore ; Madziva, Dignity ; Tau, Modiri ; Zana, Tatenda ; Gaolathe, Tendani ; Moyo, Sikhulile ; Seipone, Khumo ; Ndwapi, Ndwapi ; Essex, Max ; Marlink, Richard. / Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana : A decentralization pilot study. In: Journal of Virological Methods. 2009 ; Vol. 159, No. 1. pp. 93-97.
@article{28740efc8fa441a38bdd9369de7a10e7,
title = "Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: A decentralization pilot study",
abstract = "Roche COBAS Amplicor monitor version 1.5 assay is considered gold standard for viral load monitoring in Botswana. Due to its demand for elaborate infrastructure, viral load testing has been confined to the national HIV reference laboratories. Cavidi ExaVir Load version 2 assay was considered as a potential alternative to decentralize viral load testing to the rural/remote hospital laboratories and thus increase access to therapy. This study compared the performance of ExaVir Load v2 assay at a district hospital laboratory in Serowe and COBAS Amplicor monitor v1.5 assay at the Botswana Harvard HIV Reference Laboratory using quality assessment samples and plasma from HIV-positive individuals. ExaVir Load v2 and COBAS Amplicor monitor v1.5 assays had very good agreement; Kappa statistic 0.951. The COBAS Amplicor monitor v1.5 and ExaVir Load v2 assays detected HIV-1 RNA in 84 and 86 samples but did not detect HIV-1 RNA in 221 and 219 samples, respectively. The two assays detected HIV-1 RNA concordantly in 82 samples and were strongly correlated (r = 0.8554, P < 0.0001). ExaVir Load v2 assay provided a simple and reliable alternative viral load system that is adaptable to district hospital laboratories. The cost per test is less than RT-PCR. The ExaVir Load v2 systems have since been placed in four more district and primary hospital laboratories.",
keywords = "Cavidi ExaVir Load, HIV-1 RNA, HIV-1 RT, Resource limited, Roche COBAS Amplicor, Viral load",
author = "Madisa Mine and Keabetswe Bedi and Talkmore Maruta and Dignity Madziva and Modiri Tau and Tatenda Zana and Tendani Gaolathe and Sikhulile Moyo and Khumo Seipone and Ndwapi Ndwapi and Max Essex and Richard Marlink",
year = "2009",
month = "7",
day = "1",
doi = "https://doi.org/10.1016/j.jviromet.2009.03.008",
language = "English (US)",
volume = "159",
pages = "93--97",
journal = "Journal of Virological Methods",
issn = "0166-0934",
publisher = "Elsevier",
number = "1",

}

Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana : A decentralization pilot study. / Mine, Madisa; Bedi, Keabetswe; Maruta, Talkmore; Madziva, Dignity; Tau, Modiri; Zana, Tatenda; Gaolathe, Tendani; Moyo, Sikhulile; Seipone, Khumo; Ndwapi, Ndwapi; Essex, Max; Marlink, Richard.

In: Journal of Virological Methods, Vol. 159, No. 1, 01.07.2009, p. 93-97.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana

T2 - A decentralization pilot study

AU - Mine, Madisa

AU - Bedi, Keabetswe

AU - Maruta, Talkmore

AU - Madziva, Dignity

AU - Tau, Modiri

AU - Zana, Tatenda

AU - Gaolathe, Tendani

AU - Moyo, Sikhulile

AU - Seipone, Khumo

AU - Ndwapi, Ndwapi

AU - Essex, Max

AU - Marlink, Richard

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Roche COBAS Amplicor monitor version 1.5 assay is considered gold standard for viral load monitoring in Botswana. Due to its demand for elaborate infrastructure, viral load testing has been confined to the national HIV reference laboratories. Cavidi ExaVir Load version 2 assay was considered as a potential alternative to decentralize viral load testing to the rural/remote hospital laboratories and thus increase access to therapy. This study compared the performance of ExaVir Load v2 assay at a district hospital laboratory in Serowe and COBAS Amplicor monitor v1.5 assay at the Botswana Harvard HIV Reference Laboratory using quality assessment samples and plasma from HIV-positive individuals. ExaVir Load v2 and COBAS Amplicor monitor v1.5 assays had very good agreement; Kappa statistic 0.951. The COBAS Amplicor monitor v1.5 and ExaVir Load v2 assays detected HIV-1 RNA in 84 and 86 samples but did not detect HIV-1 RNA in 221 and 219 samples, respectively. The two assays detected HIV-1 RNA concordantly in 82 samples and were strongly correlated (r = 0.8554, P < 0.0001). ExaVir Load v2 assay provided a simple and reliable alternative viral load system that is adaptable to district hospital laboratories. The cost per test is less than RT-PCR. The ExaVir Load v2 systems have since been placed in four more district and primary hospital laboratories.

AB - Roche COBAS Amplicor monitor version 1.5 assay is considered gold standard for viral load monitoring in Botswana. Due to its demand for elaborate infrastructure, viral load testing has been confined to the national HIV reference laboratories. Cavidi ExaVir Load version 2 assay was considered as a potential alternative to decentralize viral load testing to the rural/remote hospital laboratories and thus increase access to therapy. This study compared the performance of ExaVir Load v2 assay at a district hospital laboratory in Serowe and COBAS Amplicor monitor v1.5 assay at the Botswana Harvard HIV Reference Laboratory using quality assessment samples and plasma from HIV-positive individuals. ExaVir Load v2 and COBAS Amplicor monitor v1.5 assays had very good agreement; Kappa statistic 0.951. The COBAS Amplicor monitor v1.5 and ExaVir Load v2 assays detected HIV-1 RNA in 84 and 86 samples but did not detect HIV-1 RNA in 221 and 219 samples, respectively. The two assays detected HIV-1 RNA concordantly in 82 samples and were strongly correlated (r = 0.8554, P < 0.0001). ExaVir Load v2 assay provided a simple and reliable alternative viral load system that is adaptable to district hospital laboratories. The cost per test is less than RT-PCR. The ExaVir Load v2 systems have since been placed in four more district and primary hospital laboratories.

KW - Cavidi ExaVir Load

KW - HIV-1 RNA

KW - HIV-1 RT

KW - Resource limited

KW - Roche COBAS Amplicor

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=67349153089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349153089&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.jviromet.2009.03.008

DO - https://doi.org/10.1016/j.jviromet.2009.03.008

M3 - Article

C2 - 19442851

VL - 159

SP - 93

EP - 97

JO - Journal of Virological Methods

JF - Journal of Virological Methods

SN - 0166-0934

IS - 1

ER -